Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$2.75
+2.5%
$1.96
$0.66
$3.00
$255.72M2.591.29 million shs1.37 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.22
-1.8%
$24.79
$20.92
$30.08
$143.39B0.5546.79 million shs40.31 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
+10.29%+18.58%+48.07%+54.02%+41.80%
Pfizer Inc. stock logo
PFE
Pfizer
-2.28%-5.65%+4.58%-0.38%-12.03%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$2.75
+2.5%
$1.96
$0.66
$3.00
$255.72M2.591.29 million shs1.37 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.22
-1.8%
$24.79
$20.92
$30.08
$143.39B0.5546.79 million shs40.31 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
+10.29%+18.58%+48.07%+54.02%+41.80%
Pfizer Inc. stock logo
PFE
Pfizer
-2.28%-5.65%+4.58%-0.38%-12.03%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
2.50
Moderate Buy$6.67142.78% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.37
Hold$28.4112.66% Upside

Current Analyst Ratings Breakdown

Latest CRBU and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/3/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$28.00 ➝ $30.00
10/1/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$28.00
9/27/2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Pfizer Inc. stock logo
PFE
Pfizer
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$25.00 ➝ $26.00
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$32.00 ➝ $33.00
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$27.00 ➝ $28.00
(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$9.12M28.04N/AN/A$2.79 per share0.98
Pfizer Inc. stock logo
PFE
Pfizer
$63.83B2.25$4.19 per share6.02$15.62 per share1.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$149.10M-$1.78N/AN/AN/A-1,800.93%-62.35%-49.65%11/5/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.8813.418.320.8616.84%21.42%9.12%11/4/2025 (Estimated)

Latest CRBU and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2025Q3 2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.36N/AN/AN/AN/AN/A
11/4/2025Q3 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.79N/AN/AN/A$16.94 billionN/A
8/12/2025Q2 2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.40-$0.35+$0.05-$0.58$1.64 million$2.67 million
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.58$0.78+$0.20$0.51$13.43 billion$14.65 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.82%N/A91.49%16 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/A
6.66
6.66
Pfizer Inc. stock logo
PFE
Pfizer
0.65
1.16
0.85

Institutional Ownership

CompanyInstitutional Ownership
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
77.51%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
8.28%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
10093.12 million85.41 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable

Recent News About These Companies

Doctor with Medical Healthcare Icon Interface — Photo
5 Healthcare Plays Powering the Sector’s Big Comeback
...
Leo Wealth LLC Acquires New Shares in Pfizer Inc. $PFE
US Bancorp DE Sells 491,946 Shares of Pfizer Inc. $PFE
Pfizer Inc. $PFE Stock Holdings Cut by Insight Inv LLC
PARK CIRCLE Co Purchases 65,900 Shares of Pfizer Inc. $PFE
Pfizer (NYSE:PFE) Trading Down 2.3% - Here's Why
Pfizer Sees Unusually Large Options Volume (NYSE:PFE)
Should You Buy Pfizer (PFE) Before a Breakout Begins?
Big Pharma, health care, pharmaceutical industry and medical business vintage news and newspaper printing. Abstract concept retro headlines 3d illustration. — Photo
Why AbbVie and Johnson & Johnson Could Outperform Pfizer (PFE)
...
Pfizer Inc. $PFE Shares Sold by Nelson Capital Management LLC
Matisse Capital Invests $282,000 in Pfizer Inc. $PFE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Caribou Biosciences stock logo

Caribou Biosciences NASDAQ:CRBU

$2.75 +0.07 (+2.46%)
Closing price 03:59 PM Eastern
Extended Trading
$2.74 0.00 (-0.04%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Pfizer stock logo

Pfizer NYSE:PFE

$25.22 -0.46 (-1.79%)
Closing price 03:59 PM Eastern
Extended Trading
$25.23 +0.01 (+0.04%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.